TheJakartaPost
Please Update your browser
Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.
Popular Reads
Top Results
No results found. Please check your search term and try again
Can't find what you're looking for?
View all search results
Popular Reads
Top Results
No results found. Please check your search term and try again
Can't find what you're looking for?
View all search resultsIndia to make 200 million doses of Russia's Sputnik V
The Russian Direct Investment Fund (RDIF), the country's sovereign wealth fund, said in a statement it has partnered with the Virchow Group to produce up to 200 million doses of the two-dose vaccine in India every year.
Change text size
Gift Premium Articles
to Anyone
Share the best of The Jakarta Post with friends, family, or colleagues. As a subscriber, you can gift 3 to 5 articles each month that anyone can read—no subscription needed!
FILE PHOTO: A nurse prepares Russia's Sputnik-V vaccine against the coronavirus disease (COVID-19) for inoculation in a post-registration trials stage at a clinic in Moscow, Russia September 17, 2020. (REUTERS/Tatyana Makeyeva)
T
he backer of Russia's Sputnik V coronavirus vaccine said Monday it had signed an agreement with an India-based pharmaceuticals giant for the production of up to 200 million doses of the jab a year.
The Russian Direct Investment Fund (RDIF), the country's sovereign wealth fund, said in a statement it has partnered with the Virchow Group to produce up to 200 million doses of the two-dose vaccine in India every year.
Virchow Biotech, a subsidiary of the Virchow Group, is expected to start full-scale commercial production in the first half of 2021, it said.
RDIF CEO Kirill Dmitriev said the agreement was "an important step to facilitate the full-scale local production" of Sputnik V in India and to supply partners around the world.
Last week, the RDIF announced a production agreement for at least 200 million doses of Sputnik with another Indian drugmaker -- Stelis Biopharma.
According to RDIF, Russia's vaccine, which is named after the Soviet-era satellite, has been registered in 54 countries.
Moscow registered the vaccine in August before large-scale clinical trials, but leading medical journal The Lancet has since said it is safe and over 90 percent effective.
Some Western countries have been wary of Sputnik over concerns the Kremlin is using it as a soft power tool to advance its interests.
